Vivus Muse
Executive Summary
Use of the term "urethral suppository" in a consumer print ad for the transurethral alprostadil erectile dysfunction therapy represents an "unfamiliar medical term," FDA maintains in April 1 letter to firm. "The majority of men exposed to this advertisement will not understand that Muse is a suppository designed to be inserted in the opening of a man's penis," FDA explains. Muse TV broadcast ads were the subject of a February NOV letter from FDA for inadequate information on side effects, including hypotension ("The Pink Sheet" March 9, p. 12)
You may also be interested in...
Vivus Muse Ad Omits Route Of Administration, FDA Warning Letter Says
A television advertisement for Vivus' erectile dysfunction urethral suppository Muse (alprostadil) fails to disclose the route of administration, an FDA warning letter says
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: